medical meeting

Cognition Therapeutics’ Founder/CSO to Provide Update on Elayta™ Clinical Progress at ADDF Alzheimer’s Drug Discovery Conference

PITTSBURGH, September 10, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that the company’s co-founder and chief science officer, Susan Catalano, Ph.D. will present an update on the Company’s lead candidate, Elayta™, at the 20th …

Cognition Therapeutics’ Founder/CSO to Provide Update on Elayta™ Clinical Progress at ADDF Alzheimer’s Drug Discovery Conference Read More »

Cognition Therapeutics Presenting Evidence for Elayta Synaptic Protection in Alzheimer’s Patients at Combined AAT-AD/PD Focus Meeting

Pittsburgh, March 14, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that the company’s co-founder and chief science officer, Dr. Susan Catalano, is presenting Phase 1b/2a results demonstrating the unique synaptoprotective mechanism of action …

Cognition Therapeutics Presenting Evidence for Elayta Synaptic Protection in Alzheimer’s Patients at Combined AAT-AD/PD Focus Meeting Read More »

Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at the Annual ASENT Meeting

Pittsburgh, March 6, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that Dr. Susan Catalano, Cognition’s co-founder and chief science officer, will make an oral presentation at the annual meeting of the American Society of …

Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at the Annual ASENT Meeting Read More »

Scroll to Top